Exploring the Spectrum of Long Non-Coding RNA CARMN in Physiological and Pathological Contexts

Li, Hui; Sun, Chuannan; Luo, Bin; Zhan, Chuzhi; Li, Weitao; Deng, Lu; Kang, Kang; Gou, Deming

doi:10.3390/biom14080954

Open AccessReview

Exploring the Spectrum of Long Non-Coding RNA CARMN in Physiological and Pathological Contexts

by

Hui Li

^1,†,

Chuannan Sun

^1,†,

Bin Luo

¹,

Chuzhi Zhan

¹,

Weitao Li

¹,

Lu Deng

²,

Kang Kang

^1,*

and

Deming Gou

^2,*

¹

Department of Biochemistry and Molecular Biology, Shenzhen University Medical School, Shenzhen 518060, China

²

Shenzhen Key Laboratory of Microbial Genetic Engineering, Vascular Disease Research Center, College of Life Sciences and Oceanography, Guangdong Provincial Key Laboratory of Regional Immunity and Disease, Carson International Cancer Center, School of Medicine, Shenzhen University, Shenzhen 518060, China

^*

Authors to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Biomolecules 2024, 14(8), 954; https://doi.org/10.3390/biom14080954

Submission received: 28 June 2024 / Revised: 27 July 2024 / Accepted: 2 August 2024 / Published: 6 August 2024

(This article belongs to the Special Issue Recent Advances in the Role of Translation Machinery and Translational Control in the Cardiovascular System)

Download

Browse Figures

Versions Notes

Abstract

Cardiac mesoderm enhancer-associated non-coding RNA (CARMN), an evolutionarily conserved long non-coding RNA (lncRNA), serves as the host gene for the miR143/145 cluster. It plays a crucial role in cardiovascular cell differentiation and the maintenance of vascular smooth muscle cell (VSMC) homeostasis, which are vital for normal physiological processes. Specifically, CARMN is associated with the pathological progression of cardiovascular diseases such as atherosclerosis, abdominal aortic aneurysm, and chronic heart failure. Moreover, it acts as a tumor suppressor in various cancers, including hepatocellular carcinoma, bladder cancer, and breast cancer, highlighting its potential as a beneficial biomarker and therapeutic target. This review provides a detailed examination of the roles of CARMN, its evolutionary conservation, expression patterns, and regulatory mechanisms. It also outlines its significant implications in the diagnosis, prognosis, and treatment of these diseases, underscoring the need for further translational research to exploit its clinical potential.

Keywords: long non-coding RNA; CARMN; MIR143HG; miR-143; miR-145; cardiovascular diseases; cancer

Share and Cite

MDPI and ACS Style

Li, H.; Sun, C.; Luo, B.; Zhan, C.; Li, W.; Deng, L.; Kang, K.; Gou, D. Exploring the Spectrum of Long Non-Coding RNA CARMN in Physiological and Pathological Contexts. Biomolecules 2024, 14, 954. https://doi.org/10.3390/biom14080954

AMA Style

Li H, Sun C, Luo B, Zhan C, Li W, Deng L, Kang K, Gou D. Exploring the Spectrum of Long Non-Coding RNA CARMN in Physiological and Pathological Contexts. Biomolecules. 2024; 14(8):954. https://doi.org/10.3390/biom14080954

Chicago/Turabian Style

Li, Hui, Chuannan Sun, Bin Luo, Chuzhi Zhan, Weitao Li, Lu Deng, Kang Kang, and Deming Gou. 2024. "Exploring the Spectrum of Long Non-Coding RNA CARMN in Physiological and Pathological Contexts" Biomolecules 14, no. 8: 954. https://doi.org/10.3390/biom14080954

APA Style

Li, H., Sun, C., Luo, B., Zhan, C., Li, W., Deng, L., Kang, K., & Gou, D. (2024). Exploring the Spectrum of Long Non-Coding RNA CARMN in Physiological and Pathological Contexts. Biomolecules, 14(8), 954. https://doi.org/10.3390/biom14080954

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Exploring the Spectrum of Long Non-Coding RNA CARMN in Physiological and Pathological Contexts

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI